Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival

被引:106
|
作者
Koukourakis, MI [1 ]
Giatromanolaki, A
Kakolyris, S
O'Byrne, KJ
Apostolikas, N
Skarlatos, J
Gatter, KC
Harris, AL
机构
[1] Univ Hosp Irakl, Dept Radiotherapy Oncol, Iraklion 71110, Greece
[2] Univ Hosp Irakl, St Nikolas Histopathol Unit, Iraklion 71110, Greece
[3] Oxford Radcliffe Hosp, Dept Cellular Sci, Oxford OX3 7LJ, England
[4] Oxford Radcliffe Hosp, Dept ICRF, Med Oncol Unit, Oxford OX3 7LJ, England
[5] Hellen Canc Inst, Dept Radiat Oncol, Athens, Greece
[6] Hellen Canc Inst, Dept Histopathol, Athens, Greece
关键词
PD-ECGF; thymidine phosphorylase fibroblast; macrophage; lung cancer;
D O I
10.1038/bjc.1998.280
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is recognized as an important step in tumour pathogenesis that is related to invasion and metastatic spread and which consequently results in poor clinical outcome. In this study, we have examined the role of tumour stroma-activated fibroblasts and macrophage infiltration in the development of the angiogenic and metastatic phenotype in non-small-cell lung cancer (NSCLC). A total of 141 cases of early stage I-Il NSCLC treated with surgery alone were analysed. The JC-70 (anti-CD31) MAb was used for the assessment of vascular grade. The P-GF.44C MAb was used to assess thymidine phosphorylase (TP) reactivity in cancer cells, stromal fibroblasts and macrophages, Cancer cell TP overexpression related to high vascular grade and to advanced T stage (P = 0.0004 and P = 0.02). Expression of TP in stromal fibroblasts also correlated with high angiogenesis (P = 0.01), but was independent of cancer cell expression. Fibroblast TP overexpression was related to abundant stroma (P=0.003), suggesting that TP may be a marker of active stroma, Moreover, intense macrophage infiltration was associated with fibroblast TP reactivity, regardless of the amount of stroma, suggesting that macrophages may be a major contributor to TP expression in stroma. Survival analysis showed that cancer cell TP overexpression was related to poor prognosis (P = 0.005). Although stroma TP is related to angiogenesis, in the low vascular grade group it defined a group of patients with better prognosis (P = 0.02). It may be that fibroblast TP reactivity is an indirect marker of tumour infiltration by functional macrophages, which have an anti-tumour effect, We conclude that stromal macrophage and fibroblast TP reactivity may have an important role in non-small-cell lung cancer behaviour. Understanding the role of stromal fibroblasts and inflammatory cells and their interaction with oncoprotein expression is essential for the elucidation of lung cancer pathogenesis.
引用
收藏
页码:1696 / 1703
页数:8
相关论文
共 50 条
  • [41] Immunotherapy for non-small-cell lung cancer
    Thomas, Anish
    Jakopovic, Marko
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1061 - 1064
  • [42] Staging of Non-Small-Cell Lung Cancer
    Akhurst, Tim
    PET CLINICS, 2018, 13 (01) : 1 - +
  • [43] LncRNAs in Non-Small-Cell Lung Cancer
    Ginn, Lucy
    Shi, Lei
    La Montagna, Manuela
    Garofalo, Michela
    NON-CODING RNA, 2020, 6 (03)
  • [44] Osimertinib for non-small-cell Lung Cancer
    Alakus, Hakan
    Zander, Thomas
    Bruns, Christiane
    ONKOLOGE, 2018, 24 (02): : 174 - 176
  • [45] Adagrasib in Non-Small-Cell Lung Cancer
    Kotecha, Rupesh
    Sahgal, Arjun
    Mehta, Minesh P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (13): : 1238 - 1239
  • [46] Erlotinib in non-small-cell lung cancer
    Gridelli, Cesare
    Rossi, Antonio
    Malone, Paolo
    Colantuoni, Giuseppe
    Del Gaizo, Filomena
    Ferrara, Carmine
    Nicolella, Dario
    Guerriero, Ciro
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2579 - 2592
  • [47] Non-Small-Cell Lung Cancer: Then and Now
    Schiller, Joan H.
    Gandara, David R.
    Goss, Glenwood D.
    Vokes, Everett E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 981 - 983
  • [48] Chemotherapy for non-small-cell lung cancer
    Satoh, H
    Sekizawa, K
    LANCET, 2001, 358 (9289): : 1270 - 1271
  • [49] Cetuximab in non-small-cell lung cancer
    Pirker, Robert
    Filipits, Martin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (01) : 54 - 60
  • [50] Ifosfamide in non-small-cell lung cancer
    Rosell, R
    Martin, C
    Balaña, C
    ANNALS OF ONCOLOGY, 1999, 10 : 25 - 28